These Analysts Revise Their Forecasts On Harrow Following Q4 Results

Benzinga03-04

Harrow Inc. (NASDAQ:HROW) posted mixed results for the fourth quarter on Tuesday.

The eye disease medicine maker, Harrow, reported fourth quarter earnings of 17 cents per share, missing the consensus estimate of 38 cents. Sales jumped from $66.81 million to $89.09 million, beating the consensus of $88.45 million.

During the fourth quarter and full-year ended December 31, 2025, Harrow recorded $8.5 million in acquired in-process research and development expenses related to its acquisition of Melt Pharmaceuticals.

Harrow expects fiscal 2026 sales of $350 million-$365 million, below the consensus estimate of $386.26 million.

Harrow shares rose 3% to $39.76 in pre-market trading.

These analysts made changes to their price targets on Harrow following earnings announcement.

HC Wainwright & Co. analyst Yi Chen maintained Harrow with a Buy and raised the price target from $69 to $70.
Cantor Fitzgerald analyst Steve Seedhouse maintained the stock with an Overweight rating and lowered the price target from $94 to $91.

Considering buying HROW stock? Here’s what analysts think:

Photo via Shutterstock

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2616155685?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-04 22:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2616155685","market":"us","top_or_hot":-1,"title":"These Analysts Revise Their Forecasts On Harrow Following Q4 Results","media":"Benzinga","content":"<html><body><p><strong>Harrow Inc.</strong> (NASDAQ:HROW) posted mixed results for the fourth quarter on Tuesday.</p>\n<p>The eye disease medicine maker, Harrow, reported fourth quarter earnings of 17 cents per share, missing the consensus estimate of 38 cents. Sales jumped from $66.81 million to $89.09 million, beating the consensus of $88.45 million.</p>\n<p>During the fourth quarter and full-year ended December 31, 2025, Harrow recorded $8.5 million in acquired in-process research and development expenses related to its acquisition of Melt Pharmaceuticals.</p>\n<p>Harrow expects fiscal 2026 sales of $350 million-$365 million, below the consensus estimate of $386.26 million.</p>\n<p>Harrow shares rose 3% to $39.76 in pre-market trading.</p>\n<p>These analysts made changes to their price targets on Harrow following earnings announcement.</p>\n<ul>\n<li>HC Wainwright &amp; Co. analyst Yi Chen maintained Harrow with a Buy and raised the price target from $69 to $70.</li>\n<li>Cantor Fitzgerald analyst Steve Seedhouse maintained the stock with an Overweight rating and lowered the price target from $94 to $91.</li>\n</ul>\n<p><strong>Considering buying HROW stock? Here’s what analysts think:</strong> </p>\n<figure><img decoding=\"async\" height=\"520\" loading=\"lazy\" sizes=\"(max-width: 1024px) 100vw, 1024px\" src=\"https://editorial-assets.benzinga.com/wp-content/uploads/2026/03/04090607/image-74-1024x520.png\" srcset=\"https://editorial-assets.benzinga.com/wp-content/uploads/2026/03/04090607/image-74-1024x520.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2026/03/04090607/image-74-300x152.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2026/03/04090607/image-74-768x390.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2026/03/04090607/image-74.png 1222w\" width=\"1024\"/></figure>\n<p><em>Photo via Shutterstock</em></p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>These Analysts Revise Their Forecasts On Harrow Following Q4 Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThese Analysts Revise Their Forecasts On Harrow Following Q4 Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2026-03-04 22:07</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p><strong>Harrow Inc.</strong> (NASDAQ:HROW) posted mixed results for the fourth quarter on Tuesday.</p>\n<p>The eye disease medicine maker, Harrow, reported fourth quarter earnings of 17 cents per share, missing the consensus estimate of 38 cents. Sales jumped from $66.81 million to $89.09 million, beating the consensus of $88.45 million.</p>\n<p>During the fourth quarter and full-year ended December 31, 2025, Harrow recorded $8.5 million in acquired in-process research and development expenses related to its acquisition of Melt Pharmaceuticals.</p>\n<p>Harrow expects fiscal 2026 sales of $350 million-$365 million, below the consensus estimate of $386.26 million.</p>\n<p>Harrow shares rose 3% to $39.76 in pre-market trading.</p>\n<p>These analysts made changes to their price targets on Harrow following earnings announcement.</p>\n<ul>\n<li>HC Wainwright &amp; Co. analyst Yi Chen maintained Harrow with a Buy and raised the price target from $69 to $70.</li>\n<li>Cantor Fitzgerald analyst Steve Seedhouse maintained the stock with an Overweight rating and lowered the price target from $94 to $91.</li>\n</ul>\n<p><strong>Considering buying HROW stock? Here’s what analysts think:</strong> </p>\n<figure><img decoding=\"async\" height=\"520\" loading=\"lazy\" sizes=\"(max-width: 1024px) 100vw, 1024px\" src=\"https://editorial-assets.benzinga.com/wp-content/uploads/2026/03/04090607/image-74-1024x520.png\" srcset=\"https://editorial-assets.benzinga.com/wp-content/uploads/2026/03/04090607/image-74-1024x520.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2026/03/04090607/image-74-300x152.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2026/03/04090607/image-74-768x390.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2026/03/04090607/image-74.png 1222w\" width=\"1024\"/></figure>\n<p><em>Photo via Shutterstock</em></p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://www.benzinga.com/analyst-stock-ratings/price-target/26/03/51033887/these-analysts-revise-their-forecasts-on-harrow-following-q4-results","article_id":"2616155685","we_media_id":"1052270027","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2616155685","pubTimestamp":1772633255,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Benzinga","introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"summary":" ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","BK4557":"大麻股","HROW":"Harrow Health Inc"},"translate_title":"这些分析师在第四季度业绩公布后修改了对哈罗的预测","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HROW":1},"content_text":"Harrow Inc. (NASDAQ:HROW) posted mixed results for the fourth quarter on Tuesday.\nThe eye disease medicine maker, Harrow, reported fourth quarter earnings of 17 cents per share, missing the consensus estimate of 38 cents. Sales jumped from $66.81 million to $89.09 million, beating the consensus of $88.45 million.\nDuring the fourth quarter and full-year ended December 31, 2025, Harrow recorded $8.5 million in acquired in-process research and development expenses related to its acquisition of Melt Pharmaceuticals.\nHarrow expects fiscal 2026 sales of $350 million-$365 million, below the consensus estimate of $386.26 million.\nHarrow shares rose 3% to $39.76 in pre-market trading.\nThese analysts made changes to their price targets on Harrow following earnings announcement.\n\nHC Wainwright & Co. analyst Yi Chen maintained Harrow with a Buy and raised the price target from $69 to $70.\nCantor Fitzgerald analyst Steve Seedhouse maintained the stock with an Overweight rating and lowered the price target from $94 to $91.\n\nConsidering buying HROW stock? Here’s what analysts think: \n\nPhoto via Shutterstock","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2616155685","isCrawlerRequest":true}